Alternatives Capabilities

INDEPENDENT. UNIQUE. DIVERSIFIED.

We believe the right blend of alternative strategies can deliver returns well-diversified from traditional asset classes.

Capabilities Alternatives

Our teams create diversity while reducing volatility – all within cross-asset class combinations of alpha generation, risk management and efficient beta replication strategies.

vd-icon_Currency_CashPound v3

£8.9bn
Alternatives Assets Under Management

vd-icon_People_3_Group v3

27
Alternatives Investment
Professionals

vd-icon_Bulleye_Target v3

21
Average Years’ Financial
Industry Experience

As at 31 December 2022

£8.9bn
Alternatives Assets Under Management

27
Alternatives Investment
Professionals

21
Average Years’
Experience

As at 31 December 2022

David Elms quote headshot Institutional Capabilities
Quote_Double_Icon

The Janus Henderson Diversified Alternatives Team brings together a range of investment approaches and benefits from diversity of thought. The team believes in challenging conventional thinking and applying a different lens to cross-asset class investing. 

David Elms
Head of Diversified Alternatives | Portfolio Manager

Featured Strategies

Multi Strategy

This market-neutral, alternative strategy invests across a diversified set of bottom-up strategies combined with a top-down "protection" strategy.


The portfolio protection investment strategy of the Multi Strategy portfolio does not guarantee protection.

Dynamic Trend

This systematic, time-series momentum strategy seeks to capture trends in global markets.



View all alts strategies

Insights

Do fund flows affect market prices?

Is there a statistical relationship between fund flows and market price moves?

Global Perspectives: Seeking to mitigate risk with Alternatives

What can a multi-strategy alternatives approach offer investors when more traditional assets like bonds and equities are both volatile and seemingly correlated?

Biotech rides a wave of positive data

Positive clinical trial data in 2022 could lead to record drug launches over the coming year.

Alternatives

Insight from our alternatives team to help clients navigate the markets and opportunities ahead.

alts_promo-row_fg_660x440

Institutional Insights
Sign up to get relevant content delivered straight to your inbox.